M2-ApoBDs

M2-ApoBDs are apoptotic bodies derived from M2-polarized (anti-inflammatory) macrophages. These vesicles are a form of extracellular vesicle generated during the programmed cell death (apoptosis) of M2 macrophages. They have been investigated as a novel therapeutic strategy for systemic lupus erythematosus (SLE), where they selectively target and localize to the spleen, are engulfed by splenic macrophages, and induce transcriptional changes that promote regulatory T cell (Treg) differentiation and reprogramming of anti-inflammatory macrophages. This immune modulation leads to alleviation of SLE disease progression in preclinical models. The mechanism involves targeted delivery for immune regulation via efferocytosis-mediated signaling pathways[3]. More broadly, apoptotic bodies including those from other sources have shown potential in treating inflammation, tumors, immune disorders, tissue regeneration, atherosclerosis, diabetes, hepatic fibrosis, wound healing and enhancing chemotherapy effects[1][2].

Other names

M2 macrophage-derived apoptotic bodiesM-2 macrophage-derived apoptotic bodiesM 2 macrophage-derived apoptotic bodiesM2 macrophage ApoBDsM-2 macrophage ApoBDsM 2 macrophage ApoBDs